SNCA and Parkinson disease: For example, EVs targeted with the RVG peptide and loaded with shRNA designed to decrease the levels of mRNA that code for alpha-synuclein, a protein highly involved in the pathology of PD, successfully decreased the levels of alpha-synuclein protein in the cells [83].